Title: A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma1
Principal Investigator: Andrew J Yee, MD, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Description: This open-label, phase 2 trial (ClinicalTrials.gov Identifier: NCT02718833) is recruiting participants with relapsed and refractory multiple myeloma who have received at least 2 prior therapies with at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor to evaluate the activity and safety of elotuzumab plus pomalidomide, bortezomib, and dexamethasone.
Continue Reading
The primary endpoints are overall response rate by International Myeloma Working Group criteria and the incidence of treatment-related adverse events. The secondary outcome measure is progression-free survival.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02718833.
Status: This study is recruiting patients as of February 24, 2017.
Elotuzumab is a SLAMF7-directed immunostimulatory antibody approved by the U.S. Food and Drug Administration in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1 to 3 prior therapies.
Reference
- ClinicalTrials.gov. A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma. NCT02718833. https://clinicaltrials.gov/ct2/show/NCT02718833. Accessed February 24, 2017.
